Ex­ci­sion Bio­Ther­a­peu­tics’ at­tempt to gene ed­it HIV dis­ap­points. The com­pa­ny will now re­vamp vec­tor: #AS­GCT24

BAL­TI­MORE — HIV pa­tients who re­ceived a CRISPR-based gene edit­ing treat­ment de­vel­oped by Ex­ci­sion Bio­Ther­a­peu­tics saw the virus re­bound, and now the com­pa­ny is go­ing back to the lab to de­vel­op the ex­per­i­men­tal treat­ment with a new vec­tor.

In Ex­ci­sion’s Phase 1 study, five pa­tients re­ceived a gene edit­ing ther­a­py for HIV. Three pa­tients were tak­en off their stan­dard an­ti­retro­vi­ral ther­a­py, but then had to re­turn to stan­dard treat­ments, ac­cord­ing to clin­i­cal tri­al re­sults shared Fri­day at the Amer­i­can So­ci­ety of Gene & Cell Ther­a­py’s an­nu­al meet­ing in Bal­ti­more.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER